Latest news with #MedaSystems
Business Wire
30-07-2025
- Business
- Business Wire
MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth
MENLO PARK, Calif.--(BUSINESS WIRE)--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide. 'I'm thrilled to join MedaSystems and help transform the way BioPharma and physicians collaborate to provide compliant, compassionate access to investigational therapies." Share 'Anton brings a rare combination of deep life‑sciences expertise and a growth‑mindset leadership style that aligns perfectly with our culture,' said Brian Irwin, Chief Executive Officer of MedaSystems. 'His track record of building high‑performing, customer‑centric teams will be instrumental at this pivotal moment as we enter our next phase of rapid expansion.' White joins MedaSystems after more than two decades of success driving revenue and building award‑winning teams at Optum Life Sciences, Eli Lilly, Celgene, and OptumRx. At Optum, he oversaw national sales and strategic partnerships, delivering data, analytics, and clinical‑services solutions to top‑10 global pharma companies and emerging biotech companies. 'I'm thrilled to join MedaSystems and help transform the way BioPharma and physicians collaborate to provide compliant, compassionate access to investigational therapies,' said Anton White, Vice President of Growth, MedaSystems. 'Together we'll empower sponsors and investigators with software that streamlines regulatory processes and accelerates patient access to life‑changing treatments.' White holds an MBA in Pharmaceutical & Healthcare Marketing from Saint Joseph's University, a BA in Management and Spanish from Gettysburg College, and a Sales Team Management Strategies certificate from Columbia Business School Executive Education. About MedaSystems MedaSystems is the leading developer of secure, GxP‑compliant software for managing requests for experimental therapies—including Expanded Access, Post‑Trial Access, and Investigator‑Initiated Studies. By connecting physicians and pharmaceutical companies in a centralized, audit‑ready environment, MedaSystems reduces administrative burden, improves data quality, and helps patients worldwide gain timely access to investigational treatments.
Associated Press
30-07-2025
- Business
- Associated Press
MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth
MENLO PARK, Calif.--(BUSINESS WIRE)--Jul 30, 2025-- MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide. This press release features multimedia. View the full release here: Anton White, Vice President of Growth, MedaSystems 'Anton brings a rare combination of deep life‑sciences expertise and a growth‑mindset leadership style that aligns perfectly with our culture,' said Brian Irwin, Chief Executive Officer of MedaSystems. 'His track record of building high‑performing, customer‑centric teams will be instrumental at this pivotal moment as we enter our next phase of rapid expansion.' White joins MedaSystems after more than two decades of success driving revenue and building award‑winning teams at Optum Life Sciences, Eli Lilly, Celgene, and OptumRx. At Optum, he oversaw national sales and strategic partnerships, delivering data, analytics, and clinical‑services solutions to top‑10 global pharma companies and emerging biotech companies. 'I'm thrilled to join MedaSystems and help transform the way BioPharma and physicians collaborate to provide compliant, compassionate access to investigational therapies,' said Anton White, Vice President of Growth, MedaSystems. 'Together we'll empower sponsors and investigators with software that streamlines regulatory processes and accelerates patient access to life‑changing treatments.' White holds an MBA in Pharmaceutical & Healthcare Marketing from Saint Joseph's University, a BA in Management and Spanish from Gettysburg College, and a Sales Team Management Strategies certificate from Columbia Business School Executive Education. About MedaSystems MedaSystems is the leading developer of secure, GxP‑compliant software for managing requests for experimental therapies—including Expanded Access, Post‑Trial Access, and Investigator‑Initiated Studies. By connecting physicians and pharmaceutical companies in a centralized, audit‑ready environment, MedaSystems reduces administrative burden, improves data quality, and helps patients worldwide gain timely access to investigational treatments. View source version on CONTACT: Media ContactAimee Caton Vice President, Marketing MedaSystems +1 650 515 1295 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: TECHNOLOGY HOSPITALS CLINICAL TRIALS HEALTH TECHNOLOGY SOFTWARE BIOTECHNOLOGY HEALTH PHARMACEUTICAL DATA MANAGEMENT SOURCE: MedaSystems Copyright Business Wire 2025. PUB: 07/30/2025 06:05 AM/DISC: 07/30/2025 06:05 AM
Yahoo
19-03-2025
- Business
- Yahoo
MedaSystems Launches Major New Product Release to Accelerate Automation, Configurability, and Security Requirements for its Global Customers
MENLO PARK, Calif., March 19, 2025--(BUSINESS WIRE)--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), today announced a significant new product release that aims to improve and automate the user experience of life sciences companies when receiving, processing, and acting on requests from physicians for expanded and managed access use cases. These new product enhancements will offer a seamless and secure process for accelerating approval decisions, reducing repetitive manual work, and collaborating with health care providers. "We're excited to introduce this new suite of features providing enhanced flexibility and configuration options," said Jeffrey Thibeault, CTO of MedaSystems. "This allows companies of all sizes to effectively transition their existing manual processes to a secure, intuitive, and modern platform." Key improvements with this release include: Upgraded global administrator controls, enabling country-specific configuration for program access and workflows. Workflow branching with stackable workflows and checklists that are now compatible with new and existing patient treatments. An enhanced Docusign integration will support multiple ordered signers, ensuring secure and unalterable patient documents. Improved workflows allow tasks to be auto-assigned to users based on their role within a case for greater efficiency. To showcase these advancements further, MedaSystems will host a webinar on April 10 at 10 am PT/ 1 pm ET to demonstrate the new automation, configurability, and security enhancements. Senior leadership will be available to answer questions and discuss additional features that may be of interest. This webinar is a great opportunity to engage with us directly as we shape the future of Expanded Access technology together. Register today! About MedaSystems MedaSystems is the leading developer of software for managing requests for experimental therapies, supporting Expanded Access, Post-Trial Access, and Investigator-Initiated Studies. Its secure, GxP-compliant application serves as a centralized environment that connects physicians and pharmaceutical companies, facilitating global patient access to investigational therapies. By enabling seamless tracking, inquiry management, and data collection, MedaSystems transforms communication between clinicians and life sciences teams, significantly reducing administrative burden and improving collaboration. For more information, please visit or visit our LinkedIn page. View source version on Contacts Aimee CatonVP, Marketing(650) 515-1295 Sign in to access your portfolio
Yahoo
05-03-2025
- Business
- Yahoo
MedaSystems Secures Additional Seed Financing to Advance Its AI-Driven Workflow Platform for Expanded Access and Investigator-Initiated Studies
MENLO PARK, Calif., March 05, 2025--(BUSINESS WIRE)--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), today announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems. This investment underscores confidence in MedaSystems' ability to modernize pre-approval access pathways through its AI-driven workflow platform. By streamlining Expanded Access and IIS workflows, MedaSystems helps pharmaceutical companies and healthcare providers efficiently manage requests, improve patient access, and capture real-world data (RWD) to support evidence generation and regulatory submissions. "This funding reflects the growing industry need for cloud-powered solutions that solve an historically manual challenge in Expanded Access and Investigator-Initiated Studies. With advances in AI and automation, our platform is poised to streamline other domain-critical workflows in life sciences," said Brian Irwin, CEO of MedaSystems. "This investment fuels the advancement of new platform capabilities in support of our life sciences partners' mission to deliver pre-approval treatments efficiently. Expanded Access programs, in the form of compassionate use and physician-led studies, are emerging sources of critical real-world data and directly support drug development and label expansion." MedaSystems' SaaS platform automates and streamlines Expanded Access and Investigator-Initiated Study processes, enabling faster responses to treatment inquiries and enhancing real-world data capture for regulatory submissions. The platform provides a centralized hub for healthcare providers, pharmaceutical companies, and regulatory partners to collaborate seamlessly. Physicians can efficiently manage patient requests in-app, working alongside their teams and pharmacists, while life sciences companies can integrate external partners, such as contract research organizations (CROs), to ensure coordinated communication, workflow automation, and expedited treatment delivery. "I believe in the power of health technology to improve patient outcomes and streamline operational processes for both health system providers and life science companies," said Young Sohn, Board Director. "MedaSystems is delivering speed and efficiency to this paradigm through its platform, the first of its kind in life sciences." About MedaSystems MedaSystems is the leading developer of software for managing requests for experimental therapies, supporting Expanded Access, Post-Trial Access, and Investigator-Initiated Studies. Its secure, GxP-compliant application serves as a centralized environment that connects physicians and pharmaceutical companies, facilitating global patient access to investigational therapies. By enabling seamless tracking, inquiry management, and data collection, MedaSystems transforms communication between clinicians and life sciences teams, significantly reducing administrative burden and improving collaboration. * About Expanded Access: Expanded Access (also known as Managed Access or Compassionate Use) allows patients with a serious or life-threatening condition, who have exhausted the standard of care and are not eligible to participate in clinical trials, to request access to investigational therapies that have not yet gained authorization from local regulatory authorities. Read more here. For more information, please visit View source version on Contacts Aimee Caton(650) 515-1295 Sign in to access your portfolio
Associated Press
05-03-2025
- Business
- Associated Press
MedaSystems Secures Additional Seed Financing to Advance Its AI-Driven Workflow Platform for Expanded Access and Investigator-Initiated Studies
MENLO PARK, Calif.--(BUSINESS WIRE)--Mar 5, 2025-- MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), today announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems. This investment underscores confidence in MedaSystems' ability to modernize pre-approval access pathways through its AI-driven workflow platform. By streamlining Expanded Access and IIS workflows, MedaSystems helps pharmaceutical companies and healthcare providers efficiently manage requests, improve patient access, and capture real-world data (RWD) to support evidence generation and regulatory submissions. This press release features multimedia. View the full release here: (Graphic: Business Wire) 'This funding reflects the growing industry need for cloud-powered solutions that solve an historically manual challenge in Expanded Access and Investigator-Initiated Studies. With advances in AI and automation, our platform is poised to streamline other domain-critical workflows in life sciences,' said Brian Irwin, CEO of MedaSystems. 'This investment fuels the advancement of new platform capabilities in support of our life sciences partners' mission to deliver pre-approval treatments efficiently. Expanded Access programs, in the form of compassionate use and physician-led studies, are emerging sources of critical real-world data and directly support drug development and label expansion.' MedaSystems' SaaS platform automates and streamlines Expanded Access and Investigator-Initiated Study processes, enabling faster responses to treatment inquiries and enhancing real-world data capture for regulatory submissions. The platform provides a centralized hub for healthcare providers, pharmaceutical companies, and regulatory partners to collaborate seamlessly. Physicians can efficiently manage patient requests in-app, working alongside their teams and pharmacists, while life sciences companies can integrate external partners, such as contract research organizations (CROs), to ensure coordinated communication, workflow automation, and expedited treatment delivery. 'I believe in the power of health technology to improve patient outcomes and streamline operational processes for both health system providers and life science companies,' said Young Sohn, Board Director. 'MedaSystems is delivering speed and efficiency to this paradigm through its platform, the first of its kind in life sciences.' MedaSystems is the leading developer of software for managing requests for experimental therapies, supporting Expanded Access, Post-Trial Access, and Investigator-Initiated Studies. Its secure, GxP-compliant application serves as a centralized environment that connects physicians and pharmaceutical companies, facilitating global patient access to investigational therapies. By enabling seamless tracking, inquiry management, and data collection, MedaSystems transforms communication between clinicians and life sciences teams, significantly reducing administrative burden and improving collaboration. * About Expanded Access: Expanded Access (also known as Managed Access or Compassionate Use) allows patients with a serious or life-threatening condition, who have exhausted the standard of care and are not eligible to participate in clinical trials, to request access to investigational therapies that have not yet gained authorization from local regulatory authorities. Read more here. (650) 515-1295 SOURCE: MedaSystems Copyright Business Wire 2025. PUB: 03/05/2025 06:05 AM/DISC: 03/05/2025 06:05 AM
